Therefore, the low specificity and sensitivity of the PSA test can lead to potential overdiagnosis and overtreatment, and there is an urgent need for a highly accurate and noninvasive alternative for the early diagnosis of PCa and CSPCa and to reduce unnecessary biopsies, especially for patients who fall within the PSA gray zone. The gene discussed is KLK3; the disease is posterior cortical atrophy.